• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Radiologix’s revenue rises

Article

Revenue for radiology service networks operator Radiologix increased by 37% in the first quarter of 2000 (ending March 31). First-quarter revenue was $59.3 million compared to $43.2 million for the first quarter of 1999. Net income increased 5% to $4.1

Revenue for radiology service networks operator Radiologix increased by 37% in the first quarter of 2000 (ending March 31). First-quarter revenue was $59.3 million compared to $43.2 million for the first quarter of 1999. Net income increased 5% to $4.1 million in the first quarter of 2000, compared to $3.9 million in the first quarter of 1999.

Radiologix gains most of its revenue from service fees associated with the production and management of diagnostic imaging, including MR, ultrasound, CT, mammography, nuclear medicine and PET, along with general radiography and fluoroscopy. The company’s freestanding radiology centers provide services that have been outsourced by hospitals.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.